Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs

• Autores: Marianne Martinello, Gregory J. Dore, Gail V. Matthews, Jason Grebely
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 32, Nº. 2, 2018 (Ejemplar dedicado a: Overcoming Barriers to Eliminate Hepatitis C), págs. 371-393
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Reinfection after direct-acting antiviral therapy may pose a challenge to hepatitis C virus elimination efforts. Reinfection risk is cited as a reason for not offering treatment to people who inject drugs. As treatment scale-up expands among populations with risks for reacquisition, acknowledgment that reinfection can and will occur is essential. Efforts to prevent and manage reinfection should be incorporated into individual- and population-level strategies. The risk of reinfection after successful treatment emphasises the need for education, harm reduction, and posttreatment surveillance. Reinfection must not be considered an impediment to treatment, if hepatitis C virus elimination is to be achieved.